CD8A and neoplasm: A ropivacaine-loaded hydrogel co-formulated with a Toll-like receptor 7 agonist significantly enhanced CD8+ T cell infiltration into tumor tissue, reducing postoperative recurrence while maintaining long-lasting analgesia [70].